TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline
TransCode Therapeutics has acquired Polynoma and secured $25 million from CK Life Sciences to advance its Phase 2 trial of TTX-MC138 and Phase 3-ready melanoma vaccine seviprotimut-L, positioning the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has entered into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the acquisition, TransCode secured a $25 million investment from CK Life Sciences Int'l (Holdings) Inc. to fund its lead microRNA candidate, TTX-MC138, through a Phase 2 clinical trial.
The acquisition and funding represent a significant strategic move that creates a unique and broader oncology pipeline for TransCode. The combination of Phase 3-ready seviprotimut-L with the company's TTX-MC138 program positions TransCode to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease. Philippe Calais, PharmD, PhD, who was appointed Chief Executive Officer following the announcement, emphasized the strategic importance of this development in creating a comprehensive oncology portfolio.
TransCode is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. The additional $25 million investment from CK Life Sciences will specifically support advancing TTX-MC138 through its Phase 2 clinical trial.
The acquisition of Polynoma brings seviprotimut-L into TransCode's pipeline, representing a late-stage asset that has advanced through clinical development for the treatment of stage IIB and IIC melanoma. This polyvalent shed antigen vaccine represents a significant addition to TransCode's oncology portfolio and complements the company's existing RNA-based therapeutic approach. The combination of these assets creates a diversified approach to cancer treatment that spans both vaccine and RNA therapeutic technologies.
For investors and stakeholders following the company's progress, the latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. The strategic moves announced position TransCode with multiple late-stage assets and strengthened financial backing to advance its oncology pipeline through critical clinical development milestones.